Clinical trials: Recurrent or Metastatic Salivary Gland Cancer of the Head and Neck, open to volunteers
- Condition Recurrent or Metastatic Salivary Gland Cancer of the Head and Neck
- Status Open to volunteers
Adenoid Cystic Carcinoma of the Salivary Gland, Recurrence
Study to Evaluate the Efficacy of Zanzalintinib in the Treatment of Relapsed or Metastatic Adenoid Cystic Carcinomas of the Head and Neck
Adenoid cystic carcinomas are rare cancers of the salivary glands. These cancers are treated with curative surgery, often followed by radiation therapy.
- Conditions
- Adenoid Cystic Carcinoma of the Salivary Gland, Recurrence, Metastatic Disease
- Trial name
- ZANACC (NCT07682675)
- Testing
- Zanzalintinib
- Where
- 2 sites in France
- Volunteers
- 51 people
- Sponsor
- UNICANCER
NSCLC Patients With EGFR Activating Mutation, Adenoid Cystic Carcinoma Metastatic
First in Human Multicenter Open Name Dose-increase, Consolidation Method to Study Safety Drug-level in Blood & Drug Metabolism Clinical Activity of Oral JBI-778 in Lung Cancer Patients With, Without Brain Metastasis IDH Mutated WHO Grade 3,4 Recurrent Glioma, Salivary Glands Tumor
This is a phase 1, multicentre, first-in-human, open-label, dose-escalation/consolidation study to investigate the safety, pharmacokinetics, pharmacodynamics, and clinical activity of orally administered JBI-778 in EGFR mutated…
- Conditions
- NSCLC Patients With EGFR Activating Mutation, Adenoid Cystic Carcinoma Metastatic, Adenoid Cystic Carcinoma of the Head and Neck
- Trial name
- NCT07755397
- Testing
- JBI-778
- Where
- 6 sites in India
- Volunteers
- 30 people
- Sponsor
- Jubilant Therapeutics India Limited
Malignant Head and Neck Neoplasm, Malignant Neoplasm
Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients"
The main goal of this phase of the study is to determine if objectively assessed Physical Activity (PA) levels in advanced-cancer patients are associated with health care provider (HCP)-assessed ECOG performance status and…
- Conditions
- Malignant Head and Neck Neoplasm, Malignant Neoplasm, Metastatic Malignant Neoplasm in the Neck, Metastatic Malignant Neoplasm in the Uterine Cervix
- Trial name
- NCT01365169
- Testing
- Exercise Intervention, Health Telemonitoring, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 590 people
- Sponsor
- M.D. Anderson Cancer Center
Metastatic Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma
Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers
This phase II trial compares the effect of usual treatment of docetaxel chemotherapy plus trastuzumab, to ado-emtansine (T-DM1) in patients with HER2-positive salivary gland cancer that has come back (recurrent), that has spread…
- Conditions
- Metastatic Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma, Stage III Major Salivary Gland Cancer AJCC v8, Stage IV Major Salivary Gland Cancer AJCC v8
- Trial name
- NCT05408845
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- 154 sites in United States
- Volunteers
- 146 people
- Sponsor
- NRG Oncology
Adenoid Cystic Carcinoma of the Head and Neck, SBRT
ADC and SBRT for Recurrent/Metastatic Salivary Gland Carcinoma
This is a single-arm, single-center, exploratory clinical study. The study plans to enroll patients with recurrent or metastatic head and neck salivary gland carcinoma (HN-SGC) .
- Conditions
- Adenoid Cystic Carcinoma of the Head and Neck, SBRT, Antibody-drug Conjugates
- Trial name
- NCT07579598
- Testing
- Becotatug Vedotin, SBRT, Becotatug Vedotin or Sacituzumab Tirumotecan
- Volunteers
- 40 people
- Sponsor
- Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University